Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Currently approved viral vector-based and mRNA-based vaccine approaches against coronavirus disease 2019 (COVID-19) consider only homologous prime-boost vaccination. After reports of thromboembolic events, several European governments recommended using AstraZeneca’s ChAdOx1-nCov-19 (ChAd) only in in...

Descripción completa

Detalles Bibliográficos
Autores principales: Barros-Martins, Joana, Hammerschmidt, Swantje I., Cossmann, Anne, Odak, Ivan, Stankov, Metodi V., Morillas Ramos, Gema, Dopfer-Jablonka, Alexandra, Heidemann, Annika, Ritter, Christiane, Friedrichsen, Michaela, Schultze-Florey, Christian, Ravens, Inga, Willenzon, Stefanie, Bubke, Anja, Ristenpart, Jasmin, Janssen, Anika, Ssebyatika, George, Bernhardt, Günter, Münch, Jan, Hoffmann, Markus, Pöhlmann, Stefan, Krey, Thomas, Bošnjak, Berislav, Förster, Reinhold, Behrens, Georg M. N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440184/
https://www.ncbi.nlm.nih.gov/pubmed/34262158
http://dx.doi.org/10.1038/s41591-021-01449-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440184/
https://www.ncbi.nlm.nih.gov/pubmed/34262158
http://dx.doi.org/10.1038/s41591-021-01449-9

Ejemplares similares